Modern principles of management of a patient with acute dorsalgia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Dorsalgia is a common musculoskeletal pain syndrome. Treatment of a patient with dorsalgia is associated with an increased risk of side effects and the occurrence of drug interactions the choice of a drug that is maximally appropriate to the patient's condition and the nature of his concomitant diseases, the use of the possibilities of combination therapy can provide an increase in the safety of the treatment process.

Full Text

Restricted Access

About the authors

Pavel R. Kamchatnov

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: pavkam7@gmail.com
MD, professor of the Department of neurology, neurosurgery and medical genetics

Alexander V. Chugunov

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

PhD, professor of the Department of neurology, neurosurgery and medical genetics

Zarema A. Ashalmagomedova

Dagestan State Medical University of the Ministry of Healthcare of Russia

assistant at the Department of neurology, medical genetics and neurosurgery

Aminat M. Shemshedinova

Dagestan State Medical University of the Ministry of Healthcare of Russia

assistant at the Department of neurology, medical genetics and neurosurgery

References

  1. Yu D., Peat G., Jordan K. et al. Estimating the population health burden of musculoskeletal conditions using primary care electronic health records. Rheumatology (Oxford). 2021; 9: keab109. doi: 10.1093/rheumatology/keab109.
  2. Парфенов В.А., Яхно Н.Н., Давыдов О.С. с соавт. Хроническая неспецифическая (скелетно-мышечная) поясничная боль. Рекомендации Российского общества по изучению боли (РОИБ). Неврология, нейропсихиатрия, психосоматика. 2019; S1: 7-16. doi: https://doi.org/10.14412/2074-2711-2019-2S-7-16.
  3. Jin Z., Wang D., Zhang H. et al. Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017. 2020; 79(8): 1014-22. doi: 10.1136/annrheumdis-2020-217050.
  4. Canizares M., Rampersaud Y. R., Badley E. The course of back pain in the Canadian population: trajectories, predictors, and outcomes. Arthritis Care Res (Hoboken). 2019; 71(12): 1660-70. doi: 10.1002/acr.23811.
  5. Safiri S., Kolahi A., Cross M. et al. Global, regional, and national burden of other musculoskeletal disorders 1990-2017: results from the Global Burden of Disease Study 2017. Rheumatology (Oxford). 2021; 60(2): 855-65. doi: 10.1093/rheumatology/keaa315.
  6. Hoy D., March L., Brooks P. et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann. Rheum. Dis. 2014; 73: 968-74. doi: 10.1136/annrheumdis-2013-204428.
  7. Montgomery W., Sato M., Nagasaka Y., Vietri J. The economic and humanistic costs of chronic lower back pain in Japan. Clinicoecon Outcomes Res. 2017; 9: 361-71. doi: 10.2147/CEOR.S134130.
  8. Juniper M., Le T., Mladsi D. The epidemiology, economic burden, and pharmaco-logical treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review. Expert Opin Pharmacother. 2009; 10(16): 2581-92. doi: 10.1517/14656560903304063.
  9. Zhang C., Zhang Z., Li Y. et al. Pain Catastrophizing is related to static postural control impairment in patients with nonspecific chronic low back pain: A cross-sectional study. Pain Res Manag. 2020; 2020: 9629526. doi: 10.1155/2020/9629526.
  10. LaRowe L., Powers J., Garey L. et al. Related anxiety, sex, and co-use of alcohol and prescription opioids among adults with chronic low back pain. Drug Alcohol Depend. 2020; 214: 108171. doi: 10.1016/j.drugalcdep.2020.108171.
  11. Manfre L., Van Goethem J. Low back pain. In: Diseases of the brain, head and neck, spine. 2020-2023. Eds.: Hodler J., Kubik-Huch R., von Schulthess G. Springer; 2020. Chapter 18. doi: 10.1007/978-3-030-38490-6_18.
  12. Гусев Е.И., Никифоров А.С., Камчатнов П.Р. Неврологические симптомы, синдромы и болезни. 2-е изд. М.: ГЭОТАР-Медиа. 2014; 1040 с. [Gusev E.I., Nikiforov A.S., Kamchatnov P.R. Neurological symptoms, syndromes and diseases. 2nd edition. Moscow: GEOTAR-Media. 2014; 1040 pp. (In Russ.)]. ISBN: 978-5-9704-3089-7.
  13. Chou R., Cote P., Randhawa K. et al. The Global Spine Care Initiative: applying evidence-based guidelines on the non-invasive management of back and neck pain to low- and middle-income communities. Eur Spine J. 2018; 27(6): 851-60. doi: 10.1007/s00586-017-5433-8.
  14. Камчатнов П.Р., Абусуева Б.А., Ханмурзаева С.Б., Ханмурзаева Н.Б. Проблемы выбора терапии у больного с дорсалгией. Терапевтический архив. 2020; 9: 102-107. doi: https://doi.org/10.26442/00403660.2020.09.000836.
  15. Castellsague J., Riera-Guardia N., Calingaert B. et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012; 35(12): 1127-46. doi: 10.2165/11633470000000000-00000.
  16. Goldstein J., Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015; 7: 31-41. doi: 10.2147/DHPS.S71976.
  17. Figueiras A., Estany-Gestal A., Aguirre C. et al. EMPHOGEN group. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. Pharmacogenet Genomics. 2016; 26(2): 66-73. doi: 10.1097/FPC.0000000000000186.
  18. Bhala N., Emberson J., Merhi A. et al. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials. Lancet. 2013; 382(9894): 769-79. doi: 10.1016/S0140-6736(13)60900-9.
  19. Licciardone J., Gatchel R., Phillips N., Aryal S. The Pain Registry for Epidemiological, Clinical, and Interventional Studies and Innovation (PRECISION): registry overview and protocol for a propensity score-matched study of opioid prescribing in patients with low back pain. J. Pain Res. 2018; 11: 1751-60. doi: 10.2147/JPR.S169275.
  20. Arfe A., Scotti L., Varas-Lorenzo C. et al. Safety of non-steroidal anti-inflammatory drugs (SOS) project consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016; 354: i4857. doi: 10.1136/bmj.i4857.
  21. Schink T., Kollhorst B., Varas Lorenzo C. et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018; 13(9): e0203362. doi: 10.1371/journal.pone.0203362.
  22. Bally M., Dendukuri N., Rich B. et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ. 2017; 357: j1909. doi: 10.1136/bmj.j1909.
  23. Minuz P., Fumagalli L., Gaino S. et al. Rapid stimulation of tyrosine phosphorylation signals downstream of G-protein-coupled receptors for thromboxane A2 in human platelets. Biochem J. 2006; 400: 127-34. doi: 10.1042/BJ20061015.
  24. Catella-Lawson F., Reilly M., Kapoor S. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl J. Med. 2001; 345(25): 1809-17. doi: 10.1056/NEJMoa003199.
  25. Schuijt M., Huntjens-Fleuren H., De Metz M., Vollaard E. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J. Pharmacol. 2009; 157: 931-34. doi: 10.1111/j.1476-5381.2009.00243.x.
  26. Mukherjee D., Nissen S., Topol E. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001; 286(8): 954-59. doi: 10.1001/jama.286.8.954.
  27. Vaithianathan R., Hockey P., Moore T., Bates D. Iatrogenic effects of COX-2 inhibitors in the US population: Findings from the Medical Expenditure Panel Survey. Drug Saf. 2009; 32(4): 335-43. doi: 10.2165/00002018-200932040-0000.
  28. Nissen S., Yeomans N., Solomon D. et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N. Engl J. Med. 2016; 375(26): 2519-29. doi: 10.1056/NEJMoa1611593.
  29. Jonhson A., Nguyen T., Day R. Do nonsteroidal anti-inflammatory drugs on affect blood pressure? A meta-analysis. Ann Intern Med. 1994; 121(4): 289-300.
  30. Janssen M., Caron M., van Rietbergen B. et al. Impairment of the chondrogenic phase of endochondral ossification in vivo by inhibition of cyclooxygenase-2. Eur Cell Mater. 2017; 34: 202-16. doi: 10.22203/eCM.v034a13.
  31. Pourakbari R., Khodadadi M., Aghebati-Maleki A. et al. The potential of exosomes in the therapy of the cartilage and bone complications; emphasis on osteoarthritis. Life Sci. 2019; 236: 116861. doi: 10.1016/j.lfs.2019.116861.
  32. Trimble J., Light B. Effect of penetration enhancers on the percutaneous delivery of pain management actives. Int J. Pharm Compd. 2016; 20(3): 250-56.
  33. Altman R., Barkin R. Topical therapy for osteoarthritis: clinical and pharmacologic perspectives. Postgrad Med. 2009; 121(2): 139-47. doi: 10.3810/pgm.2009.03.1986.
  34. Rod riguez-Merchan E. Topical therapiesforknee osteoarthritis. Postgrad Med. 2018; 130(7) :607-12. doi: 10.1080/00325481.2018.1505182.
  35. Rother M., Conaghan P. A randomized, double-blind, phase III trial in moderate os-teoarthritis knee pain comparing topical ketoprofen gel with ketoprofen-free gel. J. Rheumatol. 2013; 40(10): 1742-48. doi: 10.3899/jrheum.130192.
  36. Derry S., Wiffen P., Kalso E. et al. Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017; 5: CD008609. doi: 10.1002/14651858.CD008609.pub2.
  37. Derry S., Conaghan P., Da Silva J. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016; 4: CD007400. doi: 10.1002/14651858.CD007400.pub3.
  38. Bussin E., Cairns B., Bovard J., Scott A. Randomized controlled trial evaluating the short-term analgesic effect of topical diclofenac on chronic Achilles tendon pain: A pilot study. BMJ Open. 2017; 7(4): e015126. doi: 10.1136/bmjopen-2016-015126.
  39. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J. Pharmacol. 2000; 131(7): 1413-21. doi: 10.1038/sj.bjp.0703710.
  40. El Hajjaji H., Marcelis A., Devogelaer J.P., Manicourt D.H. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J. Rheumatol. 2003; 30(11): 2444-51.
  41. Pradal J., Vallet C.M., Frappin G. et al. Importance of the formulation in the skin delivery of topical diclofenac: not all topical diclofenac formulations are the same. J. Pain Res. 2019; 12: 1149-54. doi: 10.2147/JPR.S191300.
  42. Derry S., Moore R.A., Gaskell H. et al. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015; 2015(6): CD007402. doi: 10.1002/14651858.CD007402.pub3.
  43. Abdoulaye B. Metabolic and structural role of thiamine in nervous tissues. 2008; 28(7): 923-31. doi: 10.1007/s10571-008-9297-7.
  44. Aleshin V.A., Mkrtchyan G.V., Bunik V.I. Mechanisms of non-coenzyme action of thiamine. Biochemistry (Mosc). 2019; 84(8): 829-50. doi: 10.1134/S0006297919080017.
  45. Shible A., Ramadurai D., Gergen D., Reynol M. Dry beriberi due to thiamine deficiency associated with peripheral neuropathy and Wernicke's encephalopathy mimicking Guillain-Barre syndrome: A case report and review of the literature. Am J. Case Rep. 2019; 20: 330-34. doi: 10.12659/AJCR.914051.
  46. Cetin E., Civelek S., Andican G. et al. Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy. Minerva Med. 2013; 104(1): 93-101.
  47. Panjawatanan P., Charoenkwan P., Katanyuwong K., Choeyprasert W. Vincristine-induced polyneuropathy in a child with stage I. Wilms' tumour presenting with unilateral abducens nerve palsy. BMJ Case Rep. 2014; 2014: bcr2014204524. doi: 10.1136/bcr-2014204524.
  48. Banerjeeand R., Ragsdale S. The many faces of vitamin B12: catalysis by cobalamin-dependent enzymes. Annu Rev Biochem. 2003; 72: 209-47. doi: 10.1146/annurev.biochem.72.121801.161828.
  49. Sun Y., Lai M., Lu C. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol Taiwanica. 2005; 14(2): 48-54.
  50. Mizukami H., Ogasawara S., Yamagishi S. et al. Methylcobalamin effects on diabetic neuropathy and nerve protein kinase C. in rats. Eur J. Clin Invest. 2011; 41(4): 442-50. doi: 10.1111/j.1365-2362.2010.02430.x.
  51. Mahajan A., Sapehia D., Thakur S. et al. Effect of imbalance in folate and vitamin B12 in maternal/parental diet on global methylation and regulatory miRNAs. Sci Rep. 2019; 9(1): 17602. doi: 10.1038/s41598-019-54070-9.
  52. Okada K., Tanaka H., Temporin K. et al. Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model. Exp Neurol. 2010; 222(2): 191-203. doi: 10.1016/j. expneurol.2009.12.017.
  53. Камчатнов П.Р. Повышение эффективности и безопасности лечения пациентов с поясничной болью. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016; 10: 28-33. doi: https://doi.org/10.17116/jnevro201611610128-33.
  54. Mibielli M., Geller M., Cohen J. et al. Diclofenac plus B. vitamins versus diclofenac monotherapy in lumbago: The DOLOR study. Curr Med Res Opin 2009; 25(11): 2589-99. doi: 10.3111/13696990903246911.
  55. Deng X.-T., Han Y., Liu W.-T., Song X.-J. B. vitamins potentiate acute morphine antinociception and attenuate the development of tolerance to chronic morphine in mice. Pain Med. 2017; 18(10): 1961-74. doi: 10.1093/pm/pnw358.
  56. Левин О.С., Мосейкин И.А. Комплекс витаминов группы B. в лечении дискогенной пояснично-крестцовой радикулопатии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009; 10: 30-35.
  57. Calderon-Ospina C.-A., Nava-Mesa M. O., Ariza C. Effect of combined diclofenac and B. vitamins (thiamine, pyridoxine, and cyanocobalamin) for low back pain management: systematic review and meta-analysis. Pain Med. 2020; 21(4): 766-81. doi: 10.1093/pm/pnz216.
  58. Talaei A., Siavash M., Majidi H., Chehrei A. Vitamin B12 may be more effective than nortriptyline in improving painful diabetic neuropathy. Int J. Food Sci Nutr. 2009; 60(S5): 71-76. doi: 10.1080/09637480802406153.
  59. Abdel Shaheed C., Maher C., Williams K., McLachlan A. Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and meta-analysis. Eur J. Pain. 2017; 21(2): 228-37. doi: 10.1002/ejp.907.
  60. Qaseem A., Wilt T., McLean R. et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017; 166(7): 514-30. doi: 10.7326/M16-2367.
  61. Костенко Е.В., Петрова Л.В., Ганжула П.А. с соавт. Исследование эффективности тизанидина (Тизалуда) в комплексном лечении болевого и рефлекторного мышечно-тонического синдрома у больных с люмбальной дорсопатией. Нервные болезни. 2012; 4: 34-38.
  62. Pareek A., Chandurkar N., Chandanwale A. et al. Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J. 2009; 18(12): 1836-42. doi: 10.1007/s00586-009-1019-4.
  63. Камчатнов П.Р., Чугунов А.В., Казаков А.Ю. Стратегия выбора дифференциальной терапии у пациентов с болью в спине: новые данные и возможности. РМЖ. 2019; 1-1: 10-14.
  64. Скоромец А.А., Гехт А.Б., Галанов Д.В. с соавт. Результаты международного фармакоэпидемиологического наблюдательного проекта по применению мидокалма для лечения болевых синдромов, сопровождающихся мышечным спазмом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015; 12: 104-109. doi: https://doi.org/10.17116/jnevro2015115112104-109.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies